News from the Bench

Discover what’s going on at CST, receive our latest application notes and tips, read our science features, and learn about our products.

Subscribe

Important Ordering Details

Custom Ordering Details: Sections are cut freshly upon ordering. Please allow up to three business days for your product to be processed.

Our U.S. Offices Will Be Closing Early

Our U.S. offices will be closing early on November 24th at 6:00 PM EST.

Questions?

Find answers on our FAQs page.

ANSWERS  

Visit PhosphoSitePlus®

PTM information and tools available.

LEARN MORE

Product Description

Each control slide contains formalin fixed, paraffin-embedded KYSE 450 cells, both untreated and treated with EGF, that serve as a control for Phospho-EGFR immunostaining. Western blot analysis was performed on extracts derived from the same cells to verify the efficacy of the EGF treatment.

To be used with antibodies: 2235, 2237, 3777, 2236, 2234, 4404, 4407, 4267, 9411, 9417, 9416.


The epidermal growth factor (EGF) receptor is a transmembrane tyrosine kinase that belongs to the HER/ErbB protein family. Ligand binding results in receptor dimerization, autophosphorylation, activation of downstream signaling, internalization, and lysosomal degradation (1,2). Phosphorylation of EGF receptor (EGFR) at Tyr845 in the kinase domain is implicated in stabilizing the activation loop, maintaining the active state enzyme, and providing a binding surface for substrate proteins (3,4). c-Src is involved in phosphorylation of EGFR at Tyr845 (5). The SH2 domain of PLCγ binds at phospho-Tyr992, resulting in activation of PLCγ-mediated downstream signaling (6). Phosphorylation of EGFR at Tyr1045 creates a major docking site for the adaptor protein c-Cbl, leading to receptor ubiquitination and degradation following EGFR activation (7,8). The GRB2 adaptor protein binds activated EGFR at phospho-Tyr1068 (9). A pair of phosphorylated EGFR residues (Tyr1148 and Tyr1173) provide a docking site for the Shc scaffold protein, with both sites involved in MAP kinase signaling activation (2). Phosphorylation of EGFR at specific serine and threonine residues attenuates EGFR kinase activity. EGFR carboxy-terminal residues Ser1046 and Ser1047 are phosphorylated by CaM kinase II; mutation of either of these serines results in upregulated EGFR tyrosine autophosphorylation (10).


1.  Zwick, E. et al. (1999) Trends Pharmacol Sci 20, 408-12.

2.  Hackel, P.O. et al. (1999) Curr Opin Cell Biol 11, 184-9.

3.  Cooper, J.A. and Howell, B. (1993) Cell 73, 1051-4.

4.  Hubbard, S.R. et al. (1994) Nature 372, 746-54.

5.  Biscardi, J.S. et al. (1999) J Biol Chem 274, 8335-43.

6.  Emlet, D.R. et al. (1997) J Biol Chem 272, 4079-86.

7.  Levkowitz, G. et al. (1999) Mol Cell 4, 1029-40.

8.  Ettenberg, S.A. et al. (1999) Oncogene 18, 1855-66.

9.  Rojas, M. et al. (1996) J Biol Chem 271, 27456-61.

10.  Feinmesser, R.L. et al. (1999) J Biol Chem 274, 16168-73.



For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.
SignalSlide® is a trademark of Cell Signaling Technology, Inc.